UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

 

 

December 22, 2003

 

Anika Therapeutics, Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

Massachusetts

 

000-21326

 

04-3145961

(State or Other Jurisdiction of
Incorporation)

 

(Commission File
Number)

 

(I.R.S. Employer Identification No.)

 

 

 

 

 

160 New Boston Street, Woburn, Massachusetts

 

01801

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (781) 932-6616

 

 

 

Item 5:  Other Events and Required FD Disclosure.

 

On December 22, 2003, Anika Therapeutics, Inc. issued a press release (“Press Release”) announcing the signing of an exclusive, multi-year U.S. licensing and supply agreement with Ortho Biotech Products, L.P., a subsidiary of Johnson & Johnson, for Anika’s ORTHOVISCÒ osteoarthritis product.  A copy of the Press Release is attached hereto as Exhibit 99.1 and incorporated herein by reference in its entirety.

 

Item 7:  Financial Statements, Pro Forma Financial Information and Exhibits.

 

(c)  Exhibits

 

Exhibit No.

 

Description

99.1

 

Press Release issued by Anika Therapeutics, Inc. on December 22, 2003

 

2

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 

 

Anika Therapeutics, Inc.

 

 

 

 

 

December 24, 2003

By:

/s/ William J. Knight

 

 

 

William J. Knight

 

 

Chief Financial Officer

 

3

 

Exhibit Index

 

Exhibit No.

 

Description

99.1

 

Press Release of Anika Therapeutics, Inc. dated December 22, 2003

 

4